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Are type-2 biomarkers of any help in
asthma diagnosis?
To the Editor:
Asthma is a common chronic airway disease, the diagnosis of which remains challenging, as recently
highlighted by the great proportion of both under- and overdiagnosis [1]. The current diagnosis is based
on the conjunction of suggestive symptoms and the demonstration of an excessive airway calibre
fluctuation either by a bronchodilation test or by a bronchial challenge [2, 3].
The majority of asthma patients encountered in daily practice are seen in primary care and are patients
with mild disease [4]. Therefore, it is of critical importance to help primary care physicians to improve
diagnostic accuracy. Spirometry is essential in making the diagnosis but, unfortunately, it is not often
performed in the primary care setting in most European countries. Therefore, finding a suitable biomarker
to help clinicians to make a correct asthma diagnosis has been considered as a priority of future research
(European Asthma Research and Innovation Partnership) in the asthma field [5]. Although the question is
of great interest, there are only a few studies that have carefully assessed the value of blood biomarkers in
routine practice. In two single-centre, small-scale studies, serum IgE and blood eosinophil percentage were
found to provide limited value in asthma diagnosis, yielding good or acceptable specificity but poor
sensitivity [6, 7]. However, the airway inflammatory component of asthma may be conveniently
appreciated by measuring the level of nitric oxide in exhaled air (FENO) [8]. This test yields immediate
results and is totally noninvasive, which makes it a perfect contender to become a key test in clinical
practice.
We investigated the utility of type-2 (T2) biomarkers in diagnosing asthma along with spirometry. To this
end, we conducted a retrospective study on our large database including untreated patients referred to our
asthma clinic by two dedicated respiratory physicians for chronic or episodic respiratory symptoms that
may suggest asthma. We identified 702 patients who were without any maintenance treatment before the
investigations at our asthma clinic from October 2004 till December 2019. The diagnosis of asthma was
ascertained by lung function tests showing either significant reversibility to salbutamol (⩾12% from
baseline and 200 mL) and/or bronchial hyperresponsiveness to methacholine (provocative concentration
causing a 20% fall in forced expiratory volume in 1 s (FEV1) ⩽8 mg·mL−1) as recommended by the Global
Initiative for Asthma. Therefore, asthma was excluded if the patient tested negative to both tests. The
patients underwent a bronchodilating test, FENO measurement and blood sampling in the morning at visit
1, and a bronchial methacholine challenge 7–14 days later. Comparison between the asthmatic and
nonasthmatic groups was performed by Mann–Whitney test. Predicting values of biomarkers and
spirometric indices were assessed by receiver operating characteristic (ROC) curves from which the cut-off
providing the best combined sensitivity and specificity was derived, together with the 95% sensitivity and
specificity thresholds. Furthermore, we performed univariate and multivariate binary logistic regression to
compare the capacity of the biomarkers and the spirometric indices, alone or in combination, to predict
asthma. For each considered model, the corresponding ROC curve was derived.
The mean age of our patients was 51 years and 58% of our population were female. 57% were
never-smokers, 24% were ex-smokers and 19% were current smokers. Median baseline FEV1 was 95%
predicted. Out of the 702 patients, 349 (49.7%) were diagnosed as having asthma while 353 (50.3%) tested
negative to both bronchodilating test and bronchial challenge. Those diagnosed with asthma had a lower
median (interquartile range) FEV1 (90% (79–100%) versus 100% (91–110%) predicted, p<0.001) and
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median FEV1/forced vital capacity (FVC) ratio (76% (70–82%) versus 81% (77–85%), p<0.001), and had a
more frequent smoking history (27% and 22% ex-smokers and current smokers versus 20% and 15%,
respectively). Patients who qualified as asthmatic displayed greater median levels of blood eosinophils
(2.5% (1.4–4.0%) versus 1.8% (1.2–3.2%), p<0.001), serum total IgE (80 (19–247) versus 46
(18–121) kU·L−1, p<0.001) and FENO (22 (14–42) versus 18 (12–28) ppb, p<0.001). Among asthma
patients in whom induced sputum was successful (n=288), there were 104 (37%) who displayed sputum
eosinophils ⩾3%.
When drawing ROC curves, blood eosinophils, IgE and FENO provided areas under the curve (AUCs) <0.6
(table 1). The AUC for FEV1 and FEV1/FVC were slightly higher, reaching 0.67 for both the indices. None
of the biomarkers nor the spirometric indices provided negative or positive predictive value >0.7 (table 1).
In addition, the 95% sensitivity and specificity thresholds that can be used by the clinician to rule out or
rule in an asthma diagnosis are provided in table 1.
After binary logistic regression, both FENO and blood eosinophils were found to be significantly associated
with asthma in all tested models (p<0.01 for both) while IgE was not. Our analysis also indicated that
combining the three biomarkers did not increase the performance of the tests since the AUC remained at
0.6 (95 CI 0.56–0.64). However, when adding spirometric indices FEV1 and FEV1/FVC to T2 biomarkers,
the AUC of the model rose to 0.72 (95 CI 0.68–0.75).
We further assessed the values of biomarkers to identify patients with eosinophilic asthma in the group of
561 patients with successful sputum induction. T2 biomarkers were good at predicting eosinophilic asthma
(n=104) (table 1) with an AUC rising to 0.82 (95 CI 0.78–0.86) when all three biomarkers were combined.
By contrast, adding FEV1 and FEV1/FVC did not improve AUC, which remained at 0.82.
To the best of our knowledge, our study including >700 untreated adult patients is the largest that has
been reported so far. Another strength of our study is that asthma was carefully ascertained by lung
function testing to confirm the diagnosis, so we are confident in our reference standard. The baseline
demographics and baseline spirometric values of our population are representative of a mild asthma
population, which is the most often encountered in daily practice. Our data indicate that using T2
biomarkers as index tests, either alone or in combination, fails to provide sufficient diagnostic accuracy in
patients with suggestive symptoms of asthma. Overall, the T2 biomarkers provided good specificity but
poor sensitivity, which is in keeping with small-scale studies on IgE [7] and blood eosinophils [6, 7], and
with a recent meta-analysis on FENO [9]. This observation also supports the concept that asthma may also
be a non-T2 disease [8]. Though all belonging to the so-called T2 pathway, the three biomarkers we
investigated have distinct regulation. It was important to investigate whether the combination of three
biomarkers would improve accuracy, rather than each biomarker alone. However, our results show this not
TABLE 1 Performance of biomarkers and spirometry to diagnose asthma (upper part) and eosinophilic asthma (lower part)





FENO ppb 36 0.58 (0.54–0.62) 0.30 (0.21–0.36) 0.85 (0.78–0.89) 0.55 0.66 6 72
IgE kU·L−1 132 0.57 (0.53–0.61) 0.41 (0.32–0.46) 0.78 (0.67–0.83) 0.57 0.64 5 584
Eosinophils % 4.4 0.58 (0.54–0.62) 0.23 (0.15–0.27) 0.91 (0.83–0.94) 0.54 0.72 0.8 5.9
FEV1 % predicted 96 0.67 (0.63–0.71) 0.66 (0.57–0.72) 0.62 (0.53–0.68) 0.65 0.63 117 67




FENO ppb 31 0.76 (0.71–0.82) 0.64 (0.52–0.73) 0.80 (0.61–0.86) 0.91 0.42 10 81
IgE kU·L−1 135 0.68 (0.63–0.74) 0.61 (0.47–0.68) 0.73 (0.58–0.82) 0.89 0.34 10 672
Eosinophils % 2.5 0.77 (0.72–0.81) 0.80 (0.66–0.86) 0.63 (0.52–0.69) 0.93 0.33 1.30 6
FEV1 % predicted 90 0.60 (0.54–0.66) 0.51 (0.39–0.61) 0.66 (0.53–0.73) 0.85 0.25 120 64
FEV1/FVC % 74 0.64 (0.58–0.70) 0.5 (0.39–0.60) 0.86 (0.62–0.82) 0.86 0.30 88 65
For the global population, 349 patients had asthma and for the population with successful sputum induction 104 had eosinophilic asthma
(sputum ⩾3%). AUC: area under the curve; NPV: negative predictive value; PPV: positive predictive value; FENO: exhaled nitric oxide fraction;
FEV1: forced expiratory volume in 1 s; FVC: forced vital capacity.
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the case. In our study the performance of T2 biomarkers, either alone or combined, was actually less than
those of spirometric indices. This is not unexpected, as we can anticipate that excessive airway calibre
fluctuation, which is the fundamental trait of asthma, may be more strongly related to other flow rate
indices than to blood or airway inflammatory biomarkers.
Having said that, it does not deny the clinical value of measuring T2 biomarkers in phenotyping asthma,
once the diagnosis has been done [10]. Indeed, there is accumulating evidence that the response to inhaled
corticosteroids is dependent on the type of airway inflammation, with both sputum eosinophils [10, 11]
and elevated FENO [12, 13] being predictive of good treatment responses. We previously showed that
combining FENO, blood eosinophils and IgE may help in identifying eosinophilic asthma in large and
unselected populations with untreated and treated asthma [14]. Here, we show that FENO and blood
eosinophils both display an acceptable AUC (>0.75) with a very high negative predictive value (>0.9) to
rule out eosinophilic asthma in untreated patients.
Finally, combining the three T2 biomarkers with both FEV1 and FEV1/FVC in the same model provided
an AUC of 0.72, which is still well below what we could expect from a robust index test to help
establishing an accurate diagnosis.
We conclude that relying on T2 biomarkers to make an asthma diagnosis in patients with suggestive
symptoms lacks accuracy. The demonstration of excessive airway fluctuation by using reversibility or
bronchial challenge remains essential. Using T2 biomarkers is an acceptable strategy to rule out
eosinophilic asthma but not asthma by itself.
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